CA
TEVA icon

Cornerstone Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

Cornerstone Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,000
Closed -$156K – 840
2021
Q3 		$156K Hold
16,000
– – 0.03% 214
2021
Q2 		$158K Hold
16,000
– – 0.03% 211
2021
Q1 		$185K Hold
16,000
– – 0.04% 200
2020
Q4 		$154K Buy
+16,000
New +$153K 0.03% 203

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cornerstone Advisory's TEVA Position: Q4 2021 in Review

Cornerstone Advisory sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 16,000 shares — an estimated $156K sold.

Cornerstone Advisory first reported a position in TEVA in Q4 2020 and held it in 4 quarters. The position peaked at $185K in Q1 2021. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • Cornerstone Advisory reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Cornerstone Advisory sold 16,000 Teva Pharmaceuticals shares in Q4 2021, an estimated $156K.
  • Cornerstone Advisory first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Cornerstone Advisory's Teva Pharmaceuticals position peaked at $185K in Q1 2021.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on Cornerstone Advisory's 13F filing for Q4 2021, filed 23 Feb 2022.